iShares MSCI Hong Kong ETF vs Illumina, Inc. — how do they compare? iShares MSCI Hong Kong ETF trades at $22.11, while Illumina, Inc. trades at $187.83 (market cap $28.32B). The key difference: Illumina, Inc. is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | ILMN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $194.33 |
52-Week Low | $20.15 | $91.00 |
Market Cap | — | $28.32B |
Enterprise Value | — | $29.70B |
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.05, up 1.75% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF tracks Hong Kong equities, with recent momentum in Chinese tech stocks supporting performance. A dividend of $0.35 is scheduled for June 2026. Support and resistance cluster tightly around $22, indicating a critical price zone.
Outlook hinges on Hang Seng Index momentum and China's economic policies. Risks include regulatory scrutiny on Chinese firms and Asian market volatility. Analyst sentiment is mixed, with technical strength countered by valuation concerns in global markets.
Illumina (ILMN) trades at $191.20, up 0.61% with strong technical momentum near 52-week highs. The company shows robust fundamentals with consistent earnings beats, 19.42% net margin, and improving cash flow. Recent leadership appointments and product launches support growth narrative. Technical indicators show bullish momentum with support at $188 and resistance at $194.
Outlook remains positive with strong sequencing demand and margin expansion driving recovery. Risks include competition from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings but price target of $174.44 suggests limited upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →